Find Tazemetostat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1467052-75-0, Tazemetostat monohydrobromide, Epz-6438 monohydrobromide, E-7438 hydrobromide, Ez438, Tazemetostat (hydrobromide)
Molecular Formula
C34H45BrN4O4
Molecular Weight
653.6  g/mol
InChI Key
UQRICAQPWZSJNF-UHFFFAOYSA-N
FDA UNII
6P89T5M073

Tazemetostat
Tazemetostat Hydrobromide is the hydrobromide salt form of tazemetostat, an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.
1 2D Structure

Tazemetostat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide
2.1.2 InChI
InChI=1S/C34H44N4O4.BrH/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40;/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40);1H
2.1.3 InChI Key
UQRICAQPWZSJNF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5.Br
2.2 Other Identifiers
2.2.1 UNII
6P89T5M073
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:2)

2. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrochloride (1:1)

3. E 7438

4. E-7438 Hydrobromide

5. E7438

6. Epz-6438

7. Epz-6438 Dihydrobromide

8. Epz-6438 Monohydrobromide

9. Epz-6438 Monohydrochloride

10. Epz-6438 Trihydrochloride

11. Ez-438

12. Ez438

13. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide

14. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide

15. Tazemetostat

16. Tazemetostat Dihydrobromide

17. Tazemetostat Hydrochloride

18. Tazemetostat Monohydrobromide

19. Tazemetostat Monohydrochloride

20. Tazemetostat Trihydrochloride

21. Tazverik

2.3.2 Depositor-Supplied Synonyms

1. 1467052-75-0

2. Tazemetostat Monohydrobromide

3. Epz-6438 Monohydrobromide

4. E-7438 Hydrobromide

5. Ez438

6. Tazemetostat (hydrobromide)

7. Epz-6438 Hydrobromide

8. Tazemetostat Hydrobromide [usan]

9. Tazverik

10. Ez-438

11. 6p89t5m073

12. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:1)

13. N-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide

14. Unii-6p89t5m073

15. Tazverik (tn)

16. 1467052-77-2

17. Chembl4594260

18. Schembl15313373

19. Dtxsid101027715

20. Hy-13803c

21. Tazemetostat Hydrobromide (jan/usan)

22. Tazemetostat Hydrobromide [jan]

23. Tazemetostat Hydrobromide [who-dd]

24. Epz-6438 Hydrobromide; Tazemetostat Hbr

25. Cs-0101826

26. D11485

27. Tazemetostat Hydrobromide [orange Book]

28. Q27265267

29. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide

30. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide Hydrobromide

31. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamidehydrobromide

2.4 Create Date
2013-11-04
3 Chemical and Physical Properties
Molecular Weight 653.6 g/mol
Molecular Formula C34H45BrN4O4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Exact Mass652.26242 g/mol
Monoisotopic Mass652.26242 g/mol
Topological Polar Surface Area83.1 Ų
Heavy Atom Count43
Formal Charge0
Complexity992
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

API SUPPLIERS

read-more
read-more

01

Sterling Pharma Solutions

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

Sterling Pharma Solutions

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is indicated for the treatment of relapsed or refractory follicular lymphoma.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 21, 2025

blank

01

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is indicated for the treatment of relapsed or refractory follicular lymphoma.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 21, 2025

blank

Details:

Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 07, 2024

blank

02

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 07, 2024

blank

Details:

TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of relapsed/refractory follicular lymphoma.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2023

blank

03

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Details : TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of relapsed/refractory follicular lymphoma.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 09, 2023

blank

Details:

Eisai will provide Tazverik free of charge to the National Cancer Center Hospital as the drug to be used in a clinical trial of Tazemetostat, a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2, for pediatric and AYA patients with malignant tumors.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: National Cancer Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 04, 2023

blank

04

Eisai

Japan
arrow
IFT FIRST
Not Confirmed

Eisai

Japan
arrow
IFT FIRST
Not Confirmed

Details : Eisai will provide Tazverik free of charge to the National Cancer Center Hospital as the drug to be used in a clinical trial of Tazemetostat, a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2, for pediatric and AYA patients wi...

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 04, 2023

blank

Details:

Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-inclass, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Ipsen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition December 08, 2022

blank

05

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Details : Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-inclass, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 08, 2022

blank

Details:

The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2[1] inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Ipsen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 27, 2022

blank

06

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Details : The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2[1] inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

June 27, 2022

blank

Details:

First patient dosed in the randomized portion of symphony-1 (EZH-302), epizyme’s phase 1B/3 confirmatory study of Tazverik (tazemetostat) in combination with rituximab + lenalidomide (R2) for the treatment of follicular lymphoma.


Lead Product(s): Tazemetostat,Lenalidomide,Rituximab

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 15, 2022

blank

07

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Details : First patient dosed in the randomized portion of symphony-1 (EZH-302), epizyme’s phase 1B/3 confirmatory study of Tazverik (tazemetostat) in combination with rituximab + lenalidomide (R2) for the treatment of follicular lymphoma.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 15, 2022

blank

Details:

Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.


Lead Product(s): Tazemetostat,Lenalidomide,Rituximab

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 06, 2022

blank

08

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Details : Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 06, 2022

blank

Details:

Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.


Lead Product(s): Tazemetostat,Doxorubicin Hydrochloride

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Jefferies

Deal Size: $85.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering January 27, 2022

blank

09

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Epizyme

U.S.A
arrow
IFT FIRST
Not Confirmed

Details : Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

January 27, 2022

blank

Details:

TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.


Lead Product(s): Tazemetostat

Therapeutic Area: Oncology Brand Name: Tazverik

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 08, 2022

blank

10

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Hutchmed

Hong Kong
arrow
IFT FIRST
Not Confirmed

Details : TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resecti...

Product Name : Tazverik

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 08, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1467052-77-2 / Tazemetostat API manufacturers, exporters & distributors?

Tazemetostat manufacturers, exporters & distributors 1

80

PharmaCompass offers a list of Tazemetostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tazemetostat manufacturer or Tazemetostat supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tazemetostat manufacturer or Tazemetostat supplier.

PharmaCompass also assists you with knowing the Tazemetostat API Price utilized in the formulation of products. Tazemetostat API Price is not always fixed or binding as the Tazemetostat Price is obtained through a variety of data sources. The Tazemetostat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Tazemetostat

Synonyms

1467052-75-0, Tazemetostat monohydrobromide, Epz-6438 monohydrobromide, E-7438 hydrobromide, Ez438, Tazemetostat (hydrobromide)

Cas Number

1467052-77-2

Unique Ingredient Identifier (UNII)

6P89T5M073

About Tazemetostat

Tazemetostat Hydrobromide is the hydrobromide salt form of tazemetostat, an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.

Tazemetostat Manufacturers

A Tazemetostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tazemetostat, including repackagers and relabelers. The FDA regulates Tazemetostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tazemetostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Tazemetostat Suppliers

A Tazemetostat supplier is an individual or a company that provides Tazemetostat active pharmaceutical ingredient (API) or Tazemetostat finished formulations upon request. The Tazemetostat suppliers may include Tazemetostat API manufacturers, exporters, distributors and traders.

click here to find a list of Tazemetostat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Tazemetostat NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tazemetostat as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Tazemetostat API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Tazemetostat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Tazemetostat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tazemetostat NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Tazemetostat suppliers with NDC on PharmaCompass.

Tazemetostat GMP

Tazemetostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Tazemetostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tazemetostat GMP manufacturer or Tazemetostat GMP API supplier for your needs.

Tazemetostat CoA

A Tazemetostat CoA (Certificate of Analysis) is a formal document that attests to Tazemetostat's compliance with Tazemetostat specifications and serves as a tool for batch-level quality control.

Tazemetostat CoA mostly includes findings from lab analyses of a specific batch. For each Tazemetostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Tazemetostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Tazemetostat EP), Tazemetostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tazemetostat USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty